Discovering and developing the next generation of medicines for immune-mediated inflammatory diseases

Get in touch
LogoScroll

NEXT-GENERATION IMID TREATMENTS

We're on a mission to improve the lives of IMID patients

Every patient's biology and disease process is unique. By leveraging patient data, we identify the right drug target specific to the right patient, discovering and developing impactful new medicines that improve the lives of millions.

Icon

Proprietary real-world data, clinical data, and multi‑omics biomolecular data, and access to samples from patients

Icon

Multi‑dimensional, integrated machine learning target discovery platform

Icon

Currently yielding novel, disease‑relevant, druggable targets

Icon

Generating patient segregation methods to target drugs precisely

Icon

Translating targets into drug candidates

SOLVING INEFFICIENCIES IN MEDICINE DELIVERY

Drug development for IMID patients currently comes with high-risk side effects and 10x cost inefficiencies

$2.6B

Average cost to research and develop a drug

10%

Probability of successful drug approval

90%

Of drugs are efficacious in only 30-50% of patients

WHAT MAKES IMIDOMICS DIFFERENT

IMIDomics drug development is powered by a multidimensional, integrated, and data-driven Precision Discovery Engine™

The Precision Discovery EngineTM is our platform for uncovering the underlying mechanisms of IMID diseases based on patient data. It’s powered by clinical, real‑world, and biomolecular data generated for individual patients, maximizing the effectiveness of each drug developed, and is identifying unrecognized drug targets today.

Icon

Access to Patients and their Samples

Nationwide Spanish IMID Investigator Consortium

Icon

RWD and Clinical Data

proprietary

Every individual donates RWD, clinical data and samples. Provenance guaranteed by IMIDomics

Arrow
Icon

Biomolecular Data Generation

proprietary

GWAS, Bulk RNAseq, Proteomics, Methylomics, scRNAseq, Phenomics

Arrow
Icon

Computational Data Analysis

proprietary

Multi-dimensional ML platform applied to RWD, clinical and biomolecular datasets

Arrow
Icon

Target Discovery Prioritization

proprietary

IMIDomics methodologies select relevant targets with high confidence

Arrow
Icon

Drug Discovery for Patients

Continuous generation of discoveries as IMIDomics builds data and disease cohorts

Arrow
Icon

Drug
Development

Development portfolio, leveraging partners for specialized capabilities

Arrow

DATA DRIVEN

Meticulously collected and audited patient data feeds our analyses

>17,000

IMID patients and control subjects

>15,000

Clinical variables collected across the collection

>2M

Clinical and epidemiological data points

>1M

Sample vials of different biological specimens (whole blood, plasma, PBMCs, etc.) for molecular data generation

16

years of data and sample collection

120+

recruiting centers

300+

investigators

Targeting over eight diseases including systemic lupus erythematosus, Crohn’s, Psoriasis, Rheumatoid Arthritis, and Ulcerative Colitis

Map with numbers
Find out more

DRUG TARGET INNOVATION

The integration of multi‑dimensional analyses of individual patients allows IMIDomics to make precision‑targeted discoveries

IllustrationIllustration

MULTIPLE MODALITY EXPERTISE AT EVERY LEVEL

Precision discovery feeds full‑scale development of medicines

Our partnership with the Evotec team unlocks the scale of a full pharmaceutical operation, leveraging the power of machine learning to develop new treatments with unprecedented efficiency.

Illustration
  • Dedicated multidisciplinary team from Evotec
  • Decades of R&D experience being applied
  • Multiple programs engaged on a daily basis
  • High‑performance development capability

COLLABORATING WITH GLOBAL EXPERTS

Key partners at every stage

Patient Data and Sample Collection

Arrow

Drug Discovery and Development

Arrow

Pharmaceutical

Photo
“IMIDomics have assembled a unique and world-class platform for clinical and molecular profiling of IMID patients, biobanking and analytics”

Luisa Salter-Cid, Ph.D.,

Chief Scientific Officer at Pioneering Medicines

Photo
"IMIDomics is uniquely positioned to generate new and important insights that aid in the development of therapeutics to treat IMIDs.”

Michael Pucker,

Chairman and CEO of DNS Capital

Photo
“Evotec and IMIDomics are perfectly aligned on their goal to leverage data to discover and develop precise-acting, effective medicines of the future.”

Dr. Werner Lanthaler,

CEO of Evotec

Photo
"To access similar data and capabilities elsewhere would require multiple collaborations with individual clinics, universities, analysis labs, and expert data analytical groups."

Peter Schafer, Ph.D.,

Executive Director, Translational Medicine at Bristol-Myers Squibb

a WORLD-CLASS TEAM

Founded and led by world leaders in IMIDs, genetics, and drug discovery and development

Photo

Fred Craves Ph.D

Chairman and Chief Executive Officer

Sara Marsal M.D., Ph.D.

Co-Founder, Chief Medical Officer, Board Director

Photo

Fred Craves Ph.D.

Chairman and Chief Executive Officer

Photo

Sara Marsal M.D., Ph.D.

Co-Founder, Chief Medical Officer, Board Director

Photo

Sandy Zweifach

President, Chief Business Officer, Chairman Business Advisory Board

Photo

Manuel López-Figueroa Ph.D.

Chief Operating Officer

Photo

Susan Vuong

Chief Financial Officer

Photo

H. Daniel Perez M.D.

Chief Development Officer

Photo

Juan Harrison

Chief Administrative Officer

Photo

Antonio Julià Ph.D.

Chief Data Scientist

Photo

Fred Craves Ph.D

Chairman and Chief Executive Officer

Photo

Sara Marsal M.D., Ph.D.

Co-Founder, Chief Medical Officer, Board Director

Photo

Richard M. Myers Ph.D.

Co-Founder, Chair of SAB (President and Science Director HudsonAlpha Institute of Biotechnology)

Photo

Dan Littman M.D., Ph.D.

NYU Langone Health, Professor of Molecular Immunology at New York University, and Investigator of the Howard Hughes Medical Institute

Photo

Luisa Salter-Cid Ph.D.

Chief Scientific Officer, Pioneering Medicines (Formerly CMO, Gossamer and VP Immunology, BMS)

Photo

Severine Vermeire M.D., Ph.D.

Gastroenterology Department, Catholic University of Leuvan and President, European Crohn’s and Colitis Organization

Photo

Eric Perakslis Ph.D.

Chief Science and Digital Officer, Duke Clinical Research Institute (Formerly Head Data Sciences, Takeda and SVP R&D Information Technologies, (J&J)

Photo

Fred Craves Ph.D

Chairman and Chief Executive Officer

Photo

Sara Marsal M.D., Ph.D.

Co-Founder, Chief Medical Officer, Board Director

Photo

Dan Littman M.D., Ph.D.

NYU Langone Health, Professor of Molecular Immunology at New York University, and Investigator of the Howard Hughes Medical Institute

Photo

André Veillette M.D.

Director, Molecular Oncology Research Unit Montreal Clinical Research Institute (IRCM)

Photo

Pablo Engel M.D., Ph.D.

Professor of Immunology and Head of the Immunology Unit at the Department of Biomedical Sciences at the University of Barcelona Medical School

Photo

Arthur Weiss M.D., Ph.D.

Ephraim P. Engleman Distinguished Professor of Rheumatology at University of California, San Francisco

Photo

Lewis Lanier Ph.D.

J. Michael Bishop M.D. Distinguished Professor and Chairman of Microbiology at University of California, San Francisco, and Director of the Parker Institute for Cancer Immunotherapy

Photo

Fred Craves Ph.D

Chairman and Chief Executive Officer

Photo

Sara Marsal M.D., Ph.D.

Co-Founder, Chief Medical Officer, Board Director

Photo

Sandy Zweifach

President, Chief Business Officer, Chairman Business Advisory Board

Photo

Dan Bradbury

Executive Chairman, Equillium Managing Director, BioBrit Director, Intercept Pharma (Former CEO, Amylin)

Photo

Jessica Owens

Founding Partner, Initiate Studios & Ventures (co-founder and executive at GRAIL)

Photo

Jim Weiss

Founder & Chairman, Real Chemistry; Executive Advisor, New Mountain Capital

Photo

Fred Craves Ph.D

Chairman and Chief Executive Officer

Photo

Sara Marsal M.D., Ph.D.

Co-Founder, Chief Medical Officer, Board Director

Photo

Fred Craves Ph.D.

Chairman and Chief Executive Officer

Photo

Sara Marsal M.D., Ph.D.

Co-Founder, Chief Medical Officer, Board Director

Photo

Brian Stal

Board Director (DNS Capital)

Photo

Christiane Honisch, Ph.D.

Board Director (Evotec, Eppendorf AG, Illumina, Roche Molecular Diagnostics, Sequenom)

Christiane Honisch, Ph.D.
Christiane Honisch, Ph.D.
Board Director (Evotec, Eppendorf AG, Illumina, Roche Molecular Diagnostics, Sequenom)

Dr. Christiane Honisch is Senior Vice President of the Diagnostics Devision (Evognostics) at Evotec responsible for building novel patient stratifications based on omics technologies and machine learning along with Evotec’s drug discovery target identification.

She is an independent member of the company board of directors at PathoQuest, a genomic expert dedicated to the microbiology testing market.

With over 20 years of experience in developing assays and cutting-edge technology like next-generation sequencing and mass spectrometry for the Life Science and Diagnostics industry she joined Evotec from Eppendorf AG, where she was Head of Global Business Intelligence and Development.

Prior to Eppendorf she was Director of Microbiology Markets at Illumina, Inc. in San Diego and Director of Infectious Disease Research at Roche Molecular Diagnostics in San Francisco. Her career started as a key individual in the development of nucleic acid mass spectrometry for infectious diseases, oncology and prenatal diagnostics at Sequenom, Inc., San Diego.

Brian Stal
Brian Stal
Board Director (DNS Capital)

Prior to joining DNS Capital in 2019, Brian was a member of The Pritzker Organization in Chicago. While there, Brian was responsible for sourcing, executing and leading investments across a wide range of industries including healthcare and insurance. His previous experience includes working as a strategy consultant for Monitor Group (now Monitor Deloitte) and managing a portfolio of options and equities for Peak6 Investments. He has served on the board of directors of GreyCastle Holdings and as a shareholder representative for Vi Senior Living. He received his M.B.A. with honors from the University of Chicago Booth School of Business and his B.S. with honors and distinction from the University of Wisconsin – Madison.

Jim Weiss
Jim Weiss
Founder & Chairman, Real Chemistry; Executive Advisor, New Mountain Capital

Jim Weiss is a healthcare, biopharma, and medical tech visionary who has been recognized as one of the healthcare industry’s most influential people. He is the founder and chairman of Real Chemistry, a global health innovation company that uses real-world data, proprietary technologies, and analytical insights to solve the healthcare industry’s most significant engagement and commercialization challenges. He also serves as an executive advisor of New Mountain Capital, Real Chemistry’s investment partner. Mr. Weiss is a Board member of Indapta Therapeutics, as well as a Board member and contributor to the LAGRANT Foundation, the Cancer Research Institute, the Commons Project, and the Healthcare Businesswomen’s Association.

Jessica Owens
Jessica Owens
Founding Partner, Initiate Studios & Ventures (co-founder and executive at GRAIL)

Jessica Owens is a founding partner at Initiate Ventures and Studios. She previously served as co-founder and executive at GRAIL, where she led product strategy, marketing, and commercial. Prior to that, she was the founder and CEO of Spark Diagnostics, a digital health platform for the management of chronic neurological disorders. Additionally, she has been a partner at Kleiner Perkins and managed business strategy for Genomic Health.‍

Dan Bradbury
Dan Bradbury
Executive Chairman, Equillium Managing Director, BioBrit Director, Intercept Pharma (Former CEO, Amylin)

Dan Bradbury is a Life Sciences Executive with over 35 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market and maximize shareholder value. He is the managing member of BioBrit LLC, a life sciences consulting and investment firm, as well as executive chairman and co-founder of Equillium, (NASDAQ: EQ), a publicly traded biopharmaceutical company focused on developing products to treat severe autoimmune and inflammatory disorders. Previously, he served as President, CEO and Director of Amylin Pharmaceuticals until their acquisition by the Bristol-Myers Squibb Company. He also continues to serve on the boards of a number of leading healthcare companies.

Lewis Lanier Ph.D.
Lewis Lanier Ph.D.
J. Michael Bishop M.D. Distinguished Professor and Chairman of Microbiology at University of California, San Francisco, and Director of the Parker Institute for Cancer Immunotherapy

Lewis L. Lanier, Ph.D., is an American Cancer Society Professor, and J. Michael Bishop M.D. Distinguished Professor and Chairman of Microbiology and Immunology at the University of California, San Francisco, and Director of the Parker Institute for Cancer Immunotherapy. Dr. Lanier received his Ph.D. in Microbiology and Immunology from UNC – Chapel Hill. After postdoctoral studies, he joined the R&D Department at the Becton Dickinson Monoclonal Center, advancing to Associate Director.  In 1990, he joined the DNAX Research Institute, where he advanced to Director of Immunobiology, and in 1999 joined the faculty of UCSF.  His research group studies Natural Killer cells, which recognize and eliminate cells that have become transformed or infected by viruses. In recognition of his contributions, he was awarded the William B. Coley Award for Distinguished Research in Basic Tumor Immunology from the Cancer Research Institute (2002), received the Rose Payne Award for contributions to the field of Immunogenetics by the American Society for Histocompatibility and Immunogenetics (2005), was elected to the US National Academy of Sciences (2010), and the American Academy of Arts and Sciences (2011).  He served as President of the American Association of Immunologists (2006-2007) and was named an AAI Distinguished Fellow in 2019.

Arthur Weiss M.D., Ph.D.
Arthur Weiss M.D., Ph.D.
Ephraim P. Engleman Distinguished Professor of Rheumatology at University of California, San Francisco

Dr. Weiss received his B.A. from Johns Hopkins University and his M.D. and Ph.D. degrees from the University of Chicago. He is currently the Ephraim P. Engleman Distinguished Professor of Rheumatology at the University of California, San Francisco, where he has been on the faculty since 1985.  He served as Division Chief of Rheumatology at UCSF from 1988-2011. He was a Howard Hughes Medical Institute Investigator from 1985 to 2022. Dr. Weiss studies signal transduction in the immune system, focusing on the roles of tyrosine kinases and phosphatases in regulating lymphocyte activation and how abnormalities in tyrosine phosphorylation pathways lead to immunologically mediated diseases. He is a Member of the National Academy of Sciences, National Academy of Medicine, and a Fellow of the American Academy of Arts and Sciences. He is a co-founder and on the Scientific Advisory Board (SAB) of Nurix Therapeutics. He is also on the SABs of BlueSphere Bio, BridGene Biosciences, Genentech, and Jasper Therapeutics.

Pablo Engel M.D., Ph.D.
Pablo Engel M.D., Ph.D.
Professor of Immunology and Head of the Immunology Unit at the Department of Biomedical Sciences at the University of Barcelona Medical School

Dr. Engel obtained his M.D. and Ph.D. from the University of Barcelona. After training as a postdoctoral fellow at the Dana-Farber Cancer Institute of Harvard Medical School, Pablo became an assistant professor in the Department of Immunology at Duke University School of Medicine. He is currently a professor of immunology and head of the Immunology Unit in the Department of Biomedical Sciences at the University of Barcelona. His research is focused on lymphocyte cell-surface molecules and their role in the regulation of immune responses. He is also an expert in the production and characterization of monoclonal antibodies. In addition to his research, Pablo has been Secretary General of the European Federation of Immunological Societies.

André Veillette M.D.
André Veillette M.D.
Director, Molecular Oncology Research Unit Montreal Clinical Research Institute (IRCM)

Dr. André Veillette is a world-recognized immunologist and medical oncologist interested in signal transduction mechanisms in the immune system. Over the past three decades, he has identified and characterized numerous intracellular molecules and receptors that play a crucial role in normal immune regulation. A number of these molecules are directly or indirectly involved in the pathogenesis of leukemias, lymphomas, and other malignancies. They have also been linked to the development of immunodeficiencies and auto-immunity. These proteins are potential targets for therapeutic immunoregulation in the treatment of cancer, auto-immune diseases, and viral infections.  Dr. Veillette uses state-of-the-art genetic, molecular, biochemical, and cellular approaches to study these molecules.  His work has resulted in numerous publications in top scientific journals and the awarding of several prizes and prestigious grants.  He is invited to speak at conferences all over the world and to organize important international scientific conferences and is on the editorial board of leading scientific journals. Dr. Veillette’s research is currently funded by CIHR and the Terry Fox Research Institute.  He is the recipient of a Tier Canadian Research Chair. Dr. Veillette is a member of the COVID-19 Vaccine Task Force and the Long COVID Task Force of the Government of Canada. He is also the Executive Director of the Marathon of Hope Cancer Centres Network.

Eric Perakslis Ph.D.
Eric Perakslis Ph.D.
Chief Science and Digital Officer, Duke Clinical Research Institute (Formerly Head Data Sciences, Takeda and SVP R&D Information Technologies, (J&J)

Eric Perakslis, Ph.D. is the chief science and digital officer at the Duke Clinical Research Institute and professor of Population Health Sciences at the Duke University School of Medicine who brings deep expertise in the use of data to better understand complex diseases. He previously served as chief information officer and chief scientist (Informatics) at the U.S. Food and Drug Administration, as senior vice president and head of the Takeda R&D Data Science Institute, and as senior vice president of R&D Information Technology at Johnson & Johnson Pharmaceuticals R&D.

Severine Vermeire M.D., Ph.D.
Severine Vermeire M.D., Ph.D.
Gastroenterology Department, Catholic University of Leuvan and President, European Crohn’s and Colitis Organization

Séverine Vermeire, M.D., Ph.D. is a staff member at the Gastroenterology Department of the University Hospitals Leuven as well as professor of medicine and Research Director for the Biomedical Sciences Group at the Catholic University of Leuven. She has been actively involved in the development of therapeutics for inflammatory bowel disease and has authored more than 500 peer-reviewed articles. Dr. Vermeire previously served as president of the European Crohn’s and Colitis Organization and of the Belgian IBD Research and Development Group.

Luisa Salter-Cid Ph.D.
Luisa Salter-Cid Ph.D.
Chief Scientific Officer, Pioneering Medicines (Formerly CMO, Gossamer and VP Immunology, BMS)

Luisa Salter-Cid, Ph.D. is the chief scientific officer (CSO) at Pioneering Medicines where she is responsible for spearheading a portfolio of groundbreaking treatments. She was previously the CSO at Gossamer Bio and spent more than a decade at Bristol Myers Squibb. At Bristol Myers Squibb, she served as vice president and head of Immunology, Small Molecule Immuno-Oncology, and Genomics Discovery overseeing the development of therapeutics for autoimmune diseases and cancer.

Dan Littman M.D., Ph.D.
Dan Littman M.D., Ph.D.
NYU Langone Health, Professor of Molecular Immunology at New York University, and Investigator of the Howard Hughes Medical Institute

Dr. Littman, Ph.D., is the Helen L. and Martin S. Kimmel professor of Molecular Immunology at the Skirball Institute of Biomolecular Medicine of NYU Langone Medical Center and an Investigator at the Howard Hughes Medical lnstitute. Previously, he served as professor of Microbiology and Immunology at the University of California, San Francisco. Dr. Littman is a scientific founder and a member of the Scientific Advisory Boards of Vedanta Biosciences and Immunai and is a member of the Pfizer Board of Directors. He serves on a number of other advisory boards, including for ChemoCentryx, Inc., Vor Biopharma, the Broad Institute, the Ragon Institute of MGH, MIT and Harvard, and the Whitehead Institute.

Richard M. Myers Ph.D.
Richard M. Myers Ph.D.
Co-Founder, Chair of SAB (President and Science Director HudsonAlpha Institute of Biotechnology)

Dr. Richard M. Myers received his B.S. in Biochemistry from the University of Alabama in 1976, his Ph.D. in Biochemistry from the University of California, Berkeley in 1982, and did his postdoctoral training at Harvard University. He joined the faculty of the UCSF Medical Center in 1985 moved to Stanford University School of Medicine in 1993, where he was Professor and Chair in the Department of Genetics, and Director of the Stanford Human Genome Center. In 2008, Dr. Myers became President, Science Director and a Faculty Investigator of the HudsonAlpha Institute for Biotechnology, a non-profit research and teaching enterprise in Huntsville, Alabama. His research uses genomics to study how genes and their regulation affect a variety of human traits, including neurodegenerative and neuropsychiatric disorders, diseases of the immune system, cancer, and childhood genetic disorders. Dr. Myers serves on several advisory panels and editorial boards for the U.S. National Institutes of Health, Canada Genome Enterprises, The Coalition for the Life Sciences, and several universities. He is an Associate Editor of the journal Genome Research. He serves as a science advisor to Decheng Capital, Pfizer and several biotech companies. With Dr. Sara Marsal, he is co-founder and science advisor of IMIDomics.

Antonio Julià Ph.D.
Antonio Julià Ph.D.
Chief Data Scientist

Toni Julià, Ph.D., has over 18 years experience in the generation and analysis of high-throughput omic data in immune-mediated inflammatory diseases (IMIDs). He received a B.A. in Biology and a Ph.D. in Molecular Biology from the Autonomous University of Barcelona. Dr. Julià is currently the head of the Rheumatology Research Group at the Vall d’Hebron Research Institute in Barcelona (Spain). He has led the first genome-wide association studies in immune-mediated inflammatory diseases in a Southern European population, identifying new susceptibility genes and associated biological pathways. He has extensive experience in translational research in IMIDs, authoring several studies in this area, and is a co-inventor of granted patents on treatment individualization. He has developed several bioinformatic approaches for the analysis of high-throughput data, improving state-of-the-art methods.

Juan Harrison
Juan Harrison
Chief Administrative Officer

Juan Harrison is a biotechnology and pharmaceutical executive focused on company formation, strategy, partnering, venture investment, and licensing transactions. He is currently providing advisory services to several early-stage companies, venture capital enterprises, and academic centers. He was previously Vice President and Head of Strategic Academic Alliances at Takeda Pharmaceuticals, where he was responsible for establishing several broad drug discovery alliances, including the Tri-Institutional Therapeutics Discovery Institute (Weill Cornell Medicine, Rockefeller University, and Memorial Sloan Kettering Cancer Center), the Alliance for Innovative Medicines (Stanford University), the Seattle Partnership for Research in Innovative Therapeutics (the Fred Hutchinson Cancer Research Center, the University of Washington, and Seattle Children’s Hospital), and the Dana Farber Cancer Institute. Before leading Takeda’s SAA, he was VP at Takeda Ventures, where he invested in several companies, including Envoy Therapeutics, later acquired by Takeda. Mr. Harrison has been working in the biopharmaceutical industry since 1985 and has held senior positions in Alza Pharmaceuticals, Connetics, PowderJect, and XenoPort. He received a B.S. in Combined Science from Santa Clara University with an emphasis in Chemistry and Biochemistry.

H. Daniel Perez M.D.
H. Daniel Perez M.D.
Chief Development Officer

Dr. Perez, M.D., co-founded Naia Pharmaceuticals (US) and Naia Limited (a Cayman Islands company) and serves as chairman and chief executive officer. Prior to that, he was a venture partner at Bay City Capital. Earlier in his career, he was president and chief executive officer of Berlex Biosciences (the U.S. arm of Schering AG). He led R&D efforts in the United States, Berlin and Kobe, initiated multiple clinical trials, and oversaw the execution of numerous collaborations, licensing deals, spinouts, and acquisitions until he left the company upon its acquisition by Bayer.

Dr. Perez has published extensively and has been elected to multiple scientific societies and nominated to the National Academy of Sciences. Dr. Perez serves on the Board of Directors of Presidio Pharmaceuticals, on the Scientific Advisory Board of Cardium, and on the President’s Council for the Gladstone Institutes at the University of California, San Francisco (UCSF). Previously, he was a member of the Board of Directors of BayBio, Cleveland Biolabs, Hyperion Therapeutics, and the Scientific Advisory Board for GSK, China.

He received his medical degree in Buenos Aires, Argentina. He completed his medical training at Beth Israel-Mount Sinai in New York and a fellowship in rheumatology and immunology at New York University. He served on the faculty at New York University as an assistant professor of medicine and at the UCSF as a professor of medicine before joining the pharmaceutical industry.

Susan Vuong
Susan Vuong
Chief Financial Officer

Susan Vuong joined IMIDomics in November 2020 as Chief Financial Officer.  In this role, she manages the financial and treasury operations, accounting and tax reporting, and human resources, among other things, for the US headquarters and the Barcelona establishment. Ms. Vuong brings over 25 years of experience across corporate accounting, treasury, tax, audit, and internal controls. Before her current position, she served as Chief Financial Officer since 2010 for Bay City Capital, a leading life sciences Venture Capital firm, where she manages all aspects of accounting and tax for their VC Funds and their Management Companies. Prior to that, Ms. Vuong was an Assistant Controller at Spectrum Equity, a Senior Accountant at Episcopal Homes Foundation, an Office Manager/Accountant at Anderegg Builders, and an Accounting Assistant at A.G. Spanos Construction. Ms. Vuong received a B.S. in Business Administration, with an emphasis in accounting, at the University of the Pacific.

Manuel López-Figueroa Ph.D.
Manuel López-Figueroa Ph.D.
Chief Operating Officer

Manuel López-Figueroa, Ph.D. is the Chief Operating Officer at IMIDomics. Dr. Lopez-Figueroa is part of the Executive team and tasked with overseeing the day-to-day administrative and operational functions of IMIDomics.

In addition, Dr. López-Figueroa is the Scientific Liaison for the Pritzker Neuropsychiatric Disorders Research Consortium, a collaborative research enterprise comprised of a group of leaders in psychiatry, neuroscience, and genetics from Stanford University, University of Michigan, Cornell University, HudsonAlpha Institute of Biotech, and the University of California at Irvine.

Dr. López-Figueroa is an Advisor for Bay City Capital. He had previously served as Managing Director for the firm since 2001. Bay City Capital is one of the world’s premier life science investment firms investing in over 100 companies and with more than $1.6 billion under management.

With entrepreneurial experience starting several innovative companies in the portfolio, including BrainCells Inc. and Synchronicity Pharmaceuticals. Dr. López-Figueroa was involved in successful investments, including Ion Torrent Systems (acquired by Life Technologies), NextWave Pharmaceuticals (acquired by Pfizer), and Civitas (acquired by Acorda Therapeutics).

Dr. López-Figueroa has over 25 years of experience in the field of neuroscience, has won numerous awards during his academic research career, and has published extensively. He completed post-doctoral work at the University of Michigan and at the University of Copenhagen, Denmark. Dr. López received a Ph.D. in Medicine and Surgery and an M.S. in Molecular and Cell Biology from the Universities of Las Palmas and La Laguna, Spain, respectively.

Dr. López-Figueroa serves on the boards of Oryzon Genomics (ORY.MC) and Orfan Biotech (a BridgeBio’s Pharma (BBIO) subsidiary). He is an investment advisor to Nina Capital.

Sandy Zweifach
Sandy Zweifach
President, Chief Business Officer, Chairman Business Advisory Board

Sandy Zweifach is a senior executive with 30 years in the life sciences industry. Most recently he was Chair of Palladio Biosciences and Janpix, which were merged into Centessa Pharmaceuticals (NASDAQ: CNTA), created by Medicxi through the merger of 10 private biotech companies. Mr. Zweifach is currently the Chair of Carisma Therapeutics, the Executive Chair of Kaerus Biosciences, a Non-Executive Board Member of Compugen, Board Member of Essa Pharma, and advisor to several life science companies across several therapeutic areas. He has shepherded the growth of several significant life sciences companies, including serving as co-founder and CEO of Nuvelution Pharma, Inc, and as co-founder and CEO of Ascendancy Healthcare, Inc. He also was Managing Director and CFO of Bay City Capital.

Sara Marsal M.D., Ph.D.
Sara Marsal M.D., Ph.D.
Co-Founder, Chief Medical Officer, Board Director

Dr. Marsal graduated in Medicine and Surgery from Navarra University in 1985, after which she completed her Ph.D. at Barcelona University in 1990. She was a Rheumatology Resident at the Vall d'Hebron University Hospital (HUVH), Barcelona (1991-1994). In 2000, she started the Rheumatology Research Group in HUVH, a translational research lab on immune-mediated inflammatory diseases (IMIDs). Since 2012, she has been an associate Professor of Rheumatology at the Universitat Autònoma de Barcelona, Barcelona, Spain. Professor Marsal is currently the head of rheumatology department at the HUVH.

Professor Marsal has performed pioneering studies in genomics of IMIDs that have been published in top-tier journals in biomedical research. Using high throughput molecular analysis approaches, she has identified new molecular profiles associated with diagnosis and treatment response in this group of diseases. Since 2006, she has been the director of the IMID Consortium, a network of 90 reference clinical researchers in rheumatology, dermatology, and gastroenterology that is devoted to the discovery of new clinically useful biomarkers through multi-omic approaches. She also directs the IMID-Biobank, a large unique sample collection of >15,000 patients from the most prevalent IMID diseases. Professor Marsal serves on a variety of advisory panels from the pharmacological and biotechnological sectors. She is also a co-founder and science advisor of IMIDomics. Recently she has been appointed as a coordinator in a large H2020 European grant on combinatorial therapies in IMIDs using systems approaches.

Fred Craves Ph.D.
Fred Craves Ph.D.
Chairman and Chief Executive Officer

Fred Craves, Ph.D., is the Founder of Bay City Capital. Since launching the firm in 1997, he built Bay City Capital to become one of the world’s premier life science investment firms investing in nearly 100 companies and raising more than $1.6 billion.

As a leader in healthcare venture capital, Dr. Craves brings both scientific skills and deep operational expertise to the companies in which he invests. This allows him to source outstanding investment opportunities and to support exceptional management teams in creating value. He has been associated with some of the most significant exits in the biopharmaceutical industry, including Reliant Pharmaceuticals, a company he founded and then sold to GlaxoSmithKline in 2007 in the single largest all-cash transaction for a venture-backed biotech company at that time. He has served as Executive Vice President of Schering Berlin, Chief Executive Officer and President of Berlex Biosciences, Founding Chairman of the Board and Chief Executive Officer of Codon, and co-founder of Creative Biomolecules. Currently, he is the Chief Executive Officer of IMIDomics.

Dr. Craves has been named to the Forbes Midas List, which recognizes the most successful investors in the venture capital asset class across both the technology and healthcare industries. He currently serves on the Boards of Dermira, Imidomics, Madrigal Pharmaceuticals, Reset Therapeutics, and Twist Bioscience. Previous investments and board participation, in addition to Reliant, include Medarex, Incyte Pharmaceuticals, and Ion Torrent. He earned a B.S. in Biology from Georgetown University and a Ph.D. in Pharmacology and Toxicology from the University of California, San Francisco.

OUR INVESTORS

Backed by industry leaders

Get in touch for further information

Get in touch for further information

- please enter your name
- please enter a valid email
Let’s partner to improve lives
Thank you!
Your message has been received!
Close
Oops! Something went wrong while submitting the form.